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Preventing breast cancer before it is able to form is an ideal way to stop breast
cancer. However, there are limited existing options for prevention of breast cancer.
Changes in the breast tissue resulting from the aging process contribute to breast
cancer susceptibility and progression and may therefore provide promising targets for
prevention. Here, we describe new potential targets, immortalization and inflammaging,
that may be useful for prevention of age-related breast cancers. We also summarize
existing studies of warfarin and metformin, current drugs used for non-cancerous
diseases, that also may be repurposed for breast cancer prevention.
Keywords: breast cancer, prevention, chemoprevention, immortality, inflammaging, warfarin, metformin
INTRODUCTION
There are limited options for prevention of breast cancer. Tamoxifen, raloxifene, and aromatase
inhibitors are currently used for breast cancer prevention in the recurrence setting and have been
shown to be effective in large scale trials (Kinsinger et al., 2002). However, they are not used
in low risk scenarios due to side effects such as deep vein thrombosis (Kinsinger et al., 2002).
Epidemiological approaches to identify means to protect individuals from developing breast cancer
have been heavily influenced by age and estrogen receptor status. More than 75% of breast cancers
in the United States are diagnosed in women aged over 50 (Smigal et al., 2006; Jemal et al., 2007),
and 80% of age-related breast cancers are hormone-receptor expressing luminal subtypes, whereas
the triple negative disease is enriched among younger women (Jenkins et al., 2014). The dominant
paradigm suggests that the higher incidence of age-related cancers is due to accrual of somatic
mutations over time that alter regulation or activity of oncogenes and tumor suppressors (DePinho,
2000). A number of cancers show an exponential increase in incidence with age, consistent with the
mutation accumulation hypothesis. However, the incidence of breast cancer decreases sometime
after age 70 (Anderson et al., 2014). In addition, women from different countries, e.g., Japan
versus United States, exhibit very different distributions for the age of first breast cancer diagnosis
(Matsuno et al., 2007) despite both being industrialized nations with, we assume, similar mutation
rates (Todhunter et al., 2018). Thus, this evidence does not support accumulation of mutations
alone as an explanation of the age-related increase in breast cancer incidence. Examination of the
cellular and molecular processes that underlie aging in the breast may reveal new avenues for breast
cancer prevention.
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A number of systemic changes occur in the breast as a result
of age such as a significant decrease in estrogen production in the
transition to and during menopause. These hormonal differences
likely cause significant changes in the physical properties of
breast tissue as many studies have found that hormone changes
coincide with decreased connective tissue, increased adipose,
and discontinuities in the basement membrane, which maintains
normal polarity of the epithelium (Howeedy et al., 1990; Milanese
et al., 2006; Well et al., 2007). Furthermore, significant changes
occur as a result of age in mammary epithelial cells. For example,
dysfunctional luminal-biased progenitors and luminal cells with
acquired myoepithelial-like characteristics accumulate, whereas
tumor-suppressing myoepithelial cells decrease in proportion
(Garbe et al., 2012). These cellular changes may cause gradual
functional changes at the level of tissue structure that can corrupt
the tumor-suppressive activity of normal tissue architecture.
These and other alterations lead to tissue-level phenotypes
hypothesized to make older breast epithelia more susceptible to
transformation (reviewed in LaBarge et al., 2016).
Furthermore, experiments with normal human mammary
epithelial cells (HMEC) suggest that cells from older women
have intrinsic qualities that pre-dispose them to develop the
breast cancer subtypes that are more commonly found in
older women. When normal HMEC from post-menopausal
women are intentionally transformed to immortal states they
exhibit gene and protein expression consistent with luminal
breast cancer subtypes, whereas similarly treated cells from
younger women exhibit properties consistent with a basal
phenotype (Lee et al., 2015). Using heterochronus cell culture
models of human mammary epithelia it was shown that the
tissue microenvironment drives the age-related epigenetic and
transcriptional phenotypes of the luminal epithelial lineage
(Miyano et al., 2017). This suggests that age-related epigenetic
states may underlie the prevalence of luminal subtype breast
cancers among older women.
Aging also causes significant phenotypic changes in the
putative breast cancer cells of origin, cKit-expressing luminal-
biased epithelial progenitor cells (Lim et al., 2009). These cells
acquire a basal differentiation bias with age (Garbe et al.,
2012), due in part to gain in activity of the YAP transcription
factor (Pelissier et al., 2014), which is known to provide
access to epithelial-to-mesenchymal transition (EMT)-related
programs (Shao et al., 2014). Intriguingly, the luminal-biased
cKit-expressing epithelial progenitors that accumulate with age
were shown to express a unique signature of signaling molecules
(comprised of Axl, YAP, pS6, pPLCg2, pEGFR, CD44, and
pGSK3), which is the same protein signature that emerges in
immortal transformed luminal cells at the very earliest stages
of cancer progression (Pelissier Vatter et al., 2018). Taken
together, the aging process: (i) endows progenitor cells with
features of early cancer, (ii) causes epigenetic changes in the
epithelia that may underlie the types of breast cancers most
commonly seen in older patients, and (iii) diminishes the ability
of the tissue to resist malignant progression by eliminating the
myoepithelial gate keepers.
We speculate that successful forms of breast cancer prevention
would bolster processes that help maintain tissue integrity, such
as forcing progenitors to differentiate into harmless terminal
states, or decreasing the low-grade, chronic inflammation that
accompanies the aging process, which is thought to precede
many cancers. Alternatively, because cancer has a long preamble
and aging appears to prime cells to enter early stages of
malignant progression, targeting the transition states between
normal and malignant may be done in the context of age-
related breast cancers. In this review, we consider a number
of possible biological targets that may be exploited for breast
cancer prevention that span a continuum from theoretical, to
drug repurposing, and even ongoing cancer prevention clinical
trials. Indeed, it may be possible that common treatments for
maladies that are often age-associated could be effective as
chemoprevention for age-related breast cancers.
TARGETING THE TRANSITION TO
IMMORTALITY
Stopping cancer before it is able to form in susceptible breast
cells would be an ideal way to prevent breast cancer in general,
including age-related breast cancers. Many different molecular
changes can propel normal mammary epithelial cells toward
cancer; therefore a good first step for developing preventive
strategies is to define the processes that propel progression.
Ideally, a molecular process that exhibits the following qualities
would provide an excellent target for breast cancer prevention:
(1) Occurs in all precursor cancer cells.
(2) Occurs prior to the acquisition of malignant properties and
is required for malignancy.
(3) Does not occur in normal finite cells.
(4) Is unique to the process of oncogenesis and has limited-to-
no parallel mechanisms that can achieve the same result.
Studies to uncover processes involved in transitioning normal
finite HMEC to malignancy have shown that two molecularly
distinct barriers stop normal HMEC from gaining immortality,
an essential step in early cancer progression (Figure 1)
(Stampfer et al., 1997, 2003, 2013; Garbe et al., 2009, 2014;
Lee et al., 2015). The first is a stress-associated senescence
barrier (stasis). Cells need to inhibit the retinoblastoma pathway
in order to bypass this stasis barrier and continue dividing
(Garbe et al., 2009, 2014). The second barrier is replicative
senescence due to critically short telomeres. Cells need to
reactivate telomerase in order to overcome this barrier and
become immortal (Garbe et al., 2009, 2014). The process
involved in overcoming replicative senescence and becoming
immortal may be an ideal target for breast cancer prevention
as it meets the four criteria described above. (i) One of the
defining characteristics of all cancer cells is their ability to
proliferate indefinitely. Telomerase reactivation, which confers
immortality, is thought to occur during the pre-malignant ductal
carcinoma in situ (DCIS) stage of breast cancer progression
(Chin et al., 2004; Meeker et al., 2004). Therefore, cancer
cells achieve immortalization in their precursor population.
(ii) Obtaining immortality is crucial for cells to become
vulnerable to malignant transformation. This is due not just
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to obtaining unlimited proliferative capacity, but also due
to oncogene-induced senescence, meaning that malignancy-
causing oncogenes will only cause malignancy in cells that
have attained immortality (Olsen et al., 2002), but in contrast,
will cause finite cells to senesce and die (Olsen et al., 2002).
Therefore, therapeutics that target breast cancer precursor cells
before they become immortal could stop them from becoming
malignant. (iii) Normal finite cells never undergo the cancer-
associated immortalization process, thus normal cells should
not succumb to a therapeutic targeted toward this process. (iv)
The vast majority of human carcinoma cells use reactivation of
telomerase to achieve immortality. While some cancers use a
homology recombination-based mechanism, termed alternative
lengthening of telomeres (ALT), to become immortal, this
mechanism is rarely observed in breast and most other human
carcinomas (Bryan et al., 1997; Shay and Bacchetti, 1997;
Subhawong et al., 2009). Thus, if telomerase reactivation is
inhibited for prevention purposes, cancer precursors do not
have a ready parallel bypass mechanism to compensate. For
these reasons, the process of telomerase reactivation during
immortalization is a promising process to target for prevention
of most human carcinomas.
The molecular mechanisms that cause the immortalization
process are beginning to be uncovered and include two
phenomena. First, post-stasis cells acquire an error permissive
for expression of the telomerase gene and become conditionally
immortal (Stampfer et al., 1997, 2003; Garbe et al., 1999).
However, for sufficient telomerase activity to maintain stable
telomeres, these cells need to undergo a successful second
event that we have termed conversion (Stampfer et al., 1997,
2003; Garbe et al., 1999). The conversion process involves
a change in telomere dynamics that occurs as a result of
the initial immortalization-inducing error (Stampfer et al.,
1997, 2003; Garbe et al., 1999). Notably, the mean telomere
restriction fragment length (TRF) of immortalized HMEC lines
and most human cancers is approximately 4 kb (Stampfer
et al., 1997; Listerman et al., 2013; Barthel et al., 2017). This
is in stark contrast to all normal finite cells in the human
body whose mean TRF does not go below ∼5 kb (Harley
et al., 1990; Aubert et al., 2012). We hypothesize that the
conversion process involves a restructuring of telomeres to allow
regulation that supports maintaining short stable telomeres,
similar to what is seen in single-celled organisms such as yeast
(Shore and Bianchi, 2009).
Future research that aims to understand the molecular
features of the immortalization process will be valuable to
develop prevention therapeutics. Ideally, research should start
with normal finite cells that have been made post-stasis
following molecular perturbations that are prevalent in most
breast cancers. In order to induce and follow immortalization
we have previously studied cell lines that became immortal
following exposure to benzo(a)pyrene (Stampfer and Bartley,
1985; Stampfer et al., 1997). More recently we have been able
to induce immortalization by transduction of post-stasis HMEC
with a c-Myc transgene (Garbe et al., 2009, 2014; Lee et al.,
2015). Research with these and other models have revealed some
molecular features that may be unique to the immortalization
process, such as loss of the long non-coding RNA MORT (Nijjar
et al., 1999; Stampfer et al., 2003; Garbe et al., 2014; Lee et al.,
2015; Vrba et al., 2015). Another intriguing target may be
proliferating cell nuclear antigen (PCNA), which is thought to
undergo a post-translational modification that is detected only
in cancer and cancer precursor cells, as early as the DCIS stage
(Gu et al., 2018). There are pre-clinical molecules known to target
and kill cancer cells harboring this unique form of PCNA and
thus represent a potential prevention agent that stops recently
immortalized cells in their tracks (Gu et al., 2018). Therapeutics
designed to inhibit the cancer-associated immortalization process
may prevent a majority of breast cancers before they have
a chance to form.
TARGETING INFLAMMAGING TO
REDUCE SUSCEPTIBILITY TO BREAST
CANCER
The aging immune system is characterized by innate immune
changes that include a type of chronic, low-grade, macrophage-
centered, sterile inflammation known as inflammaging (Palmer
et al., 2018). At a basic level, inflammation is an organized
immune system response to infection or tissue injury in which
several cell types and chemical signaling molecules are recruited
to the site of injury and begin a process of wound-healing. The
most common signaling molecules involved in inflammation,
FIGURE 1 | Model of breast cancer progression and barriers for potential chemoprevention targets. Normal cells continue to divide in culture until they approach the
stress-associated stasis barrier; cells can bypass stasis by functional inhibition of the retinoblastoma pathway. Post-stasis cells continue to divide until they approach
the replicative senescence barrier, which results from ongoing telomere erosion producing telomere dysfunction and genomic instability. Reactivation of telomerase in
post-stasis cells can confer immortality. Eroded telomeres, genomic instability, and telomerase reactivation similarly occur at the DCIS stage in vivo. Our research
suggests that immortalization coincides with a cancer-unique re-structuring of telomere maintenance mechanisms. Immortalized cells are then resistant to oncogene
induced senescence (OIS) and many oncogenes can cause them to become malignant. We propose that the immortalization barrier can be a valuable target for
breast cancer prevention (starred).
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which are used as characteristic markers, include: tumor necrosis
factor-alpha (TNF-α), transforming growth factor-beta (TGF-
β), and interleukins-1, 6, and 18 (IL-1, IL-6, and IL-18)
(Bonafe et al., 2012; Prattichizzo et al., 2016; Xia et al., 2016).
Serum levels of IL-6 and C-reactive protein (CRP), are often
used to assess inflammatory levels in patients (Barbaresko
et al., 2013). Regulation of expression of pro-inflammatory
cytokines and proper timing of expression of opposing anti-
inflammatory cytokines during an immune response is needed
for homeostasis. Over-expression of pro-inflammatory cytokines
can lead to chronic inflammation and autoimmunity, and
conversely over-expression of anti-inflammatory cytokines can
lead to immune suppression.
Immune cells in normal breast tissue primarily localize to
breast lobules, where they closely associate with the epithelium,
rather than stroma or fat (Degnim et al., 2014). Murine mammary
gland studies revealed the importance of immune-epithelial cell
interactions that cause phenotypic and compositional changes
in the mammary epithelia during development (Gouon-Evans
et al., 2002; Lilla and Werb, 2010; Reed and Schwertfeger, 2010;
Plaks et al., 2015). The composition and function of immune
cell populations are known to change in peripheral blood with
age (e.g., increased macrophages and dendritic cells, decreased
T cells, and reduced function of cytotoxic T cells) (Plackett
et al., 2004; Weiskopf et al., 2009), and in breast tissue during
breast cancer progression (e.g., increased macrophages) (Ruffell
et al., 2012; Degnim et al., 2017; Linde et al., 2018). How age-
related changes in immune cell populations, and their effects on
aged mammary epithelia, are relevant to increased breast cancer
susceptibility with age is not well-understood.
The components of inflammaging that plausibly drive breast
cancer initiation and progression include age-related DNA
damage, cell senescence, and obesity. Increased DNA damage
accumulation with age is a contributing factor to inflammaging.
When mammary stem cells and stromal fibroblasts incur DNA
damage, they secrete pro-inflammatory cytokines, including IL-
6 and IL-8 that can affect surrounding cells (Dieriks et al.,
2010; Ivanov et al., 2010). The cytokines in turn induce further
DNA damage, cause alterations in the surrounding target
cells, and recruit macrophages to the area leading to more
inflammation. Inflammation further enables transformation of
the surrounding cells, and inflammatory lymphocytes and
macrophages are thought to accelerate transformation of
mammary epithelia (Lin et al., 2006; Rao et al., 2006).
Increases in senescent cells are synonymous with aging which
is associated with the senescence-associated secretory phenotype
(SASP), a phenomenon that causes senescent cells to activate
an inflammatory transcriptional program. Senescence protects
cells from transformation, but paradoxically, senescent cells
secrete a number of pro-inflammatory cytokines and matrix
metalloproteinases that act on neighboring cells in a deleterious
manner to induce changes in gene expression that are associated
with transformation (Krtolica et al., 2001; Coppe et al., 2010;
Borodkina et al., 2018). There is a long-established correlation
between the age-associated increase in obesity and breast cancer
(Picon-Ruiz et al., 2017). One plausible link between obesity
and breast cancer is the pro-tumorigenic and pro-angiogenic
microenvironment generated by increased secretion of pro-
inflammatory cytokines, like IL-6, by macrophages in adipose
tissue (Seiler et al., 2018). Thus the release of pro-inflammatory
molecules and microenvironment remodeling enzymes that
result from cell and tissue changes that are associated with
aging comprise a similar set of mechanisms that underlie the
inflammaging phenomenon.
There is an overall association between chronic low-level
inflammation and aging phenotypes in multiple tissues, however,
the actual impact on aging phenotypes of mammary epithelia
remains to be demonstrated. If there is a relationship between
inflammaging in breast with deleterious epithelial changes and
increased breast cancer susceptibility, then weight loss and anti-
inflammation strategies would comprise the main thrust of a
prevention approach. This could also include aspirin, which has
been suggested to be preventive for breast cancer through an
as-yet unknown mechanism (Clarke et al., 2017). In addition,
a number of foods are considered anti-inflammatory and may
reduce inflammaging, such as fruits, vegetables, fish, and whole
grains (Barbaresko et al., 2013; Calder et al., 2017; Kaluza
et al., 2018). Continued research examining the mechanistic
link between inflammaging and breast cancer susceptibility may
provide more useful therapeutic targets for prevention.
WARFARIN AS A PUTATIVE
PREVENTION AGENT
Warfarin is commonly prescribed in Western countries for
atrial fibrillation, venous thromboembolism, and a number
of other cardiac-related indications. Although use is steadily
declining in favor of newer anti-coagulants that have preferable
safety profiles, warfarin remains one of the most heavily
prescribed anti-coagulants with as many as seven million
users in the United States as of 2014 (Barnes et al., 2015).
A majority of warfarin users are over 60 years of age; thus
this drug is particularly intriguing in the context of age-
related breast cancer prevention. Epidemiological studies have
identified a putative cancer prevention effect of warfarin in
this older population in multiple cancer contexts. Women
who used warfarin for at least 6 months showed 10–30%
reduced relative risk of breast cancer compared to non-
warfarin users (Schulman and Lindmarker, 2000; Tagalakis
et al., 2007; Haaland et al., 2017). Similar anti-cancer effects
were reported in animal models (Ryan et al., 1968; Williamson
et al., 1980; Paolino et al., 2014), which also revealed that
warfarin doses with no anti-coagulation activity also could be
effective in a prevention context (Kirane et al., 2015), thus
potentially avoiding some of the negative safety issues associated
with warfarin use.
Warfarin inhibits vitamin K oxidoreductases, resulting
in depletion of vitamin K and non-carboxylated
γ-carboxyglutamate domains of vitamin K-dependent
proteins. Most of the ∼14 known proteins that are vitamin
K-dependent are involved in coagulation of blood; however,
growth arrest specific 6 (GAS6) and periostin (POSTN) also
require γ-carboxylation. Haaland et al. (2017) hypothesize that
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in the absence of γ-carboxylation GAS6 cannot remain anchored
in the plasma membrane and thus converts GAS6 from being
an Axl receptor tyrosine kinase agonist into an antagonist.
Inhibiting Axl has the impact of reducing malignant traits in
aggressive mammary carcinomas, as well as increasing natural
killer cell activity (Gjerdrum et al., 2010; Kirane et al., 2015). Axl
signaling is linked to induction of epithelial-to-mesenchymal
transitions in cancer cells, and induction of stem cell-like
properties, suggesting an overall role in regulation of stem-like
states (Vuoriluoto et al., 2011; Jokela et al., 2018). Although
speculative, inhibition of Axl with an antagonist-form of GAS6
may prevent cancer stem cells from remaining in a stem-like
state and instead allow them to differentiate into terminal
states (Figure 2). Another potential target of warfarin, periostin
(POSTN), is thought to improve cancer cell survival and, in some
contexts, increase proliferation by increasing microenvironment
stiffness due to collagen cross-linking. GLA-domains are protein
regions commonly modified by γ-carboxylation. POSTN harbors
28 vitamin K-dependent GLA-domains in its collagen-binding
domain, which is an unusually large number compared to 3
to 5 GLA domains in other matricellular proteins, and the
role of GLA-domain γ-carboxylation in this protein is not
well understood. POSTN is expressed by myoepithelial cells
in normal mammary epithelia. Although myoepithelial cells
are lost during aging and breast cancer progression, POSTN is
highly expressed by the carcinoma cells and cancer associated
fibroblasts (Grignani et al., 1993; Grigoriadis et al., 2006).
Preventing POSTN GLA-domain γ-carboxylation and stopping
it from exerting its effect as a pro-survival and pro-proliferative
protein may constitute a second possible mechanism for
warfarin-driven breast cancer prevention.
Additional study of warfarin use in a prevention setting
is merited based on the multiple human population and
mouse studies showing a putative protective effect. However,
contemplating the use of warfarin specifically for cancer
prevention raises a number of serious safety challenges, and a
better overall understanding of its effects at various doses in
epithelial cells and tissue is still needed.
METFORMIN FOR PREVENTION
Metformin (1,1-dimethylbiguanide hydrochloride) belongs to
the biguanide family of oral hypoglycemic agents that are used
commonly to treat type II diabetes and insulin resistance.
Insulin resistance occurs when peripheral tissues gradually
lose their ability to uptake glucose in response to insulin.
This provokes the pancreas to produce further insulin and
causes elevated serum insulin levels. Metformin lowers serum
glucose, increases insulin sensitivity in peripheral tissues and
reduces serum insulin levels by a number of mechanisms
(Rena et al., 2017). These include reducing hepatic glucose
production and inhibiting mitochondrial ATP generation
(Owen et al., 2000). Low ATP levels are sensed by AMP-
activated protein kinase (AMPK) (Hawley et al., 2010; Rena
et al., 2017), which in turn activates signaling pathways to
replenish ATP supplies. Simultaneously, AMPK inhibits ATP-
consuming synthetic pathways such as gluconeogenesis and lipid
FIGURE 2 | Proposal of a tissue-level mechanism of warfarin’s putative anti-breast cancer effects. In mammary epithelia Axl signaling allow cells with progenitor
properties access to stem-cell gene programs; engagement with the GAS6 ligand maintains progenitors in an undifferentiated state. Warfarin inhibits
gamma-carboxylation of the Axl ligand, GAS6, preventing it from remaining anchored in the plasma membrane and essentially converting GAS6 from an agonist to
an Axl-antagonist. At that point the progenitors may differentiate into more terminal states. Because the epithelial progenitors are thought to comprise breast cancer
cells of origin, it might be more advantageous to force them to differentiate before they become a liability.
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FIGURE 3 | Potential molecular mechanisms of Metformin’s anti-cancer
effects. Metformin inhibits complex 1 in the mitochondria thus reducing ATP
production. Low levels of ATP activate AMPK which inhibits mTOR. Metformin
improves peripheral tissue sensitivity to insulin and reduces insulin levels in the
blood. Reduction of downstream signaling through the insulin receptor results
in reduction of PI3K/Akt/mTOR signaling as well as RAS/MAPK signaling
leading to reduced cellular proliferation. Metformin also induces its cancer
preventative effects via inhibiting IL6 mediated activation of JAK/Stat3
signaling involved in tumorigenesis.
synthesis (Carling et al., 2011; Hardie, 2011), thus reducing
insulin resistance.
Insulin resistance is a key risk factor for age-related breast
cancers (Lipscombe et al., 2006; Kabat et al., 2009; Ibarra-
Drendall et al., 2011; Gunter et al., 2015; Luque et al., 2017). High
insulin levels are positively associated with an increased breast
cancer risk in post-menopausal women (Gunter et al., 2015). In
addition, women with serum insulin levels in the upper tertile
are more than twice as likely to develop breast cancer (Kabat
et al., 2009). High indices of insulin resistance are associated
also with poor prognosis in women with early and metastatic
stages of breast cancer (Gennari et al., 2014; Ferroni et al., 2016).
Insulin acts as a breast cancer cell mitogen directly and indirectly
via insulin-like growth factors (IGFs) (David and Linda, 2012).
When insulin binds its receptor, phosphatidylinositol 3-kinase
(PI3K) is activated, which in turn activates Akt/mTOR. Insulin
also activates Ras and subsequently mitogen-activated protein
kinase (MAPK), inducing cell proliferation and survival (David
and Linda, 2012; Figure 3). These studies suggest therapeutics
designed to treat insulin resistance may help treat breast cancer
in diabetic patients.
Epidemiologic studies revealed that metformin use is
associated with decreased cancer and cancer-associated mortality
in diabetic patients (Bowker et al., 2006; Jiralerspong et al.,
2009; Bodmer et al., 2010; Kim et al., 2018). Diabetic patients
on long-term metformin were 56% less likely to develop breast
cancer compared with control patients (Bodmer et al., 2010), and
had reduced cancer-related mortality (Bowker et al., 2006). At
a cellular level, metformin inhibits the growth of breast cancer
cells in vivo (Zakikhani et al., 2006). Metformin is thought to
be anti-neoplastic because it inhibits signaling pathways that
fuel breast cancer cell proliferation and protein synthesis. For
example, metformin activates AMPK (Hawley et al., 2010; Howell
et al., 2017; Rena et al., 2017); activated AMPK inhibits mTOR
(Howell et al., 2017) and phospho-Acetyl-CoA carboxylase
(pACC) thus leading to suppression of normal and tumor cell
growth (Ibarra-Drendall et al., 2011). Metformin’s reduction of
insulin levels reduces downstream signaling through the insulin
receptor (PI3K/AKT/mTOR) (Zi et al., 2018), and simultaneously
reduces signaling to the Ras/MAPK pathway (Ibarra-Drendall
et al., 2011; David and Linda, 2012) collectively resulting in
reduced cancer cell proliferation and survival. Through these
mechanisms metformin has potential beneficial effects in diabetic
breast cancer patients.
It is reasonable to speculate that metformin may help non-
diabetic breast cancer patients as well by targeting different
mechanisms. Indeed, metformin was shown to prevent some
aging phenotypes in vivo and in vitro (Kiho et al., 2005;
Diamanti-Kandarakis et al., 2007; Anisimov, 2010; Barzilai
et al., 2016). For example, metformin prevents the formation
of advanced glycation end products (AGEs) in vitro, which
normally accumulate in various tissues as a result of aging
and long-term diabetes (Kiho et al., 2005; Luevano-Contreras
and Chapman-Novakofski, 2010; Vlassara and Uribarri, 2014).
Metformin reduced AGE levels in women with polycystic
ovary syndrome (characterized by insulin resistance) after a
6-month-long treatment (Diamanti-Kandarakis et al., 2007).
Furthermore, metformin limited age-associated senescence
in mouse myoblasts (Jadhav et al., 2013) and prevented
SASP in human fetal lung fibroblasts (Moiseeva et al.,
2013). While it is controversial whether itself affects glucose
metabolism and insulin sensitivity (Refaie et al., 2006), especially
when accounting for lean body mass, BMI and sex (Chia
et al., 2018), there is enough evidence to suggest that
hyperinsulinemia levels accelerate aging phenotypes, promote
age-related diseases and reduces overall lifespan (Facchini
et al., 2000; Johnson and Templeman, 2016). Metformin may
slow these processes and improve healthspan by reducing
hyperinsulinemia and improving peripheral tissue insulin
sensitivity (Martin-Montalvo et al., 2013; Bannister et al., 2014).
Metformin also reduces inflammation associated with insulin
resistance, diabetes and aging (Saisho, 2015). Metformin’s
anti-inflammatory effects include inhibition of monocyte to
macrophage differentiation (Vasamsetti et al., 2015), and
inhibition of multiple pro-inflammatory cytokines and related
signaling such as IL-6, IL-1β, C-X-C motif ligand 1/2 (CXCL1/2)
and NF-κB (Cameron et al., 2016). These effects also were
observed in studies of patients with impaired fasting glucose and
diabetes (Krysiak and Okopien, 2012, 2013). Reduction in IL-6
levels due to metformin administration was shown to cause a
reduction of some cancer stem cells (Iliopoulos et al., 2011). Low
doses of metformin selectively killed breast cancer stem cells in
four different subtypes of breast cancer (Hirsch et al., 2009).
Thus, current studies suggest a beneficial role for metformin
on breast cancer prevention, treatment, and outcome. Indeed,
metformin is already being tested in a multicenter clinical trial
for its ability to prevent breast cancer in women who exhibit
atypical hyperplasia (NCT01905046). Metformin is a relatively
inexpensive and safe drug with minimal side effects. The most
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common side effect is minor gastrointestinal upset, whereas
the most serious, yet rare, one is lactic acidosis, especially in
patients with renal failure. Collectively, these factors suggest
metformin is a worthy drug candidate in the context of breast
cancer prevention.
PATIENT ADVOCATE PERSPECTIVES
Advocate #1
Notes4Hope.org is a non-profit organization that focuses on
healthy lifestyle as a means to prevent breast cancer. There are
many chemicals in our terrestrial environment, in our air, in
our household and beauty products, and in our foods that have
been linked, to one degree or another, to the development of
breast cancer. Chemical production in the United States has
increased 15-fold since the 1950s, and a number of chemicals
that are used in food production and manufacturing exert
unintended deleterious biological effects. More research is needed
to understand whether there are negative impacts on breast
tissue biology of the chemicals used in food production and
product manufacturing. Furthermore, education focused on
an individual’s incremental and sustainable choices to reduce
stress, increase wellness practices, change household and beauty
products, and consume more organic and pastured foods can
serve as basis for preventing breast cancer. We recognize that
diet and lifestyle are intrinsic to culture, and thus conscious
changes can be met with significant cultural inertia. Because
the panoply of chemicals produced for medical and commercial
purposes have as much potential to do harm as they have to
heal, the modern pharmacopeia could be used also to augment
healthy lifestyle choices. This review considers repurposing
medicines like warfarin and metformin, made originally to treat
heart disease and diabetes, to prevent breast cancer. While this
concept is appealing, as advocates, our excitement should be
counterbalanced by the same skepticism with which we view
other chemicals used for medicine and manufacturing. Further
research should be done to conclude whether or not these
medicines do affect breast biology in a positive way, and if they
can be used in a manner that does not alter an otherwise healthy
aging trajectory.
Advocate #2
Rethinking the limitations of incremental progress requires new
ideas and a collaborative ecosystem across sectors, disciplines,
and areas of expertise. Aligning experiential and professionalized
expertise and insights, advocates bring unique perspectives to
the research table as they lend support, challenge assumptions,
inspire change, and assist with responsibly advancing basic
science and translational research agendas. Peering into the
future of science to improve clinical outcomes, researchers in
the LaBarge lab have collaboratively identified innovative cutting-
edge scientific ideas on the frontiers of their respective disciplines.
Urging cautious optimism within an understanding of cell and
tissue biology, they argue that there are some opportunities
that we should consider for future prevention targets. Clearly,
the public needs awareness regarding emerging new scientific
rationales. However, advocates caution that we must not risk
fooling ourselves. There does seem to be potential benefits of
repurposing anticoagulant drugs such as warfarin or diabetes
drugs such as metformin, thus meriting renewed investigation
as potential candidates for prevention of breast cancer. Because
they act in part by inhibiting tissue-level changes associated
with aging, advocates look critically at the value proposition and
demand evidence of pill effectiveness and drug safety profiles.
If there is insufficient evidence of safety, let us not begin
giving the healthy aging population potentially toxic drugs in
the name of prevention. As vital catalysts for transdisciplinary
innovation, research advocates are thrilled to play a vital role
in shaping this effort at study inception. They enthusiastically
urge research team members to dive deeper into the scientific
as well as the humanistic applications of repurposing drugs as
anti-breast cancer agents for the aging population. Moreover,
cooperation between researchers and advocates helps encourage
team members to speak up about the landscape of uncertainties
encountered as they jointly tackle what accounts for the
uniqueness of breast cancer prevention in the aging population.
DISCUSSION
Our intention with this review is to stimulate thinking around
how breast cancer prevention might be approached differently
by considering the mechanisms driving change in breast tissue
that are consequences of aging – the single greatest risk factor
for breast cancer. Herein, we examined a continuum from
highly theoretical aspects of breast tissue biology that represent
potential prevention targets, such as the transition between
normal and immortal states, to treatment modalities that are
already in some form of clinical deployment. We hypothesized
that age-related changes in the tissue may create a susceptible
microenvironment for breast cancer progression that can be
targeted with drugs for preventing breast cancer. Epidemiological
evidence suggests that two existing drugs, warfarin and
metformin, typically used for non-cancer diseases, merit renewed
investigation as potential candidates for prevention of breast
cancer and that they act in part by inhibiting tissue-level
changes associated with aging. However, even in our optimism
toward the repurposing of these drugs, it must be respected
that these drugs (warfarin in particular) can have dangerous
side effects. Thus, it will be crucial to understand whether
the animal experiments, showing that sub-therapeutic doses of
warfarin can exert anti-cancer effects, are safely translatable
to humans. If the negative impacts of these decades-old
medications cannot be sufficiently mitigated to warrant testing
in a normal risk population, then use in high-risk populations
could be considered, as is currently the case for metformin.
The aging immune system also likely contributes to aging
phenotypes that, at the tissue level, contribute to breast
cancer and is therefore an important area of research that
may provide novel targets for prevention of age-associated
breast cancer. The consequences of age-related shifts in the
immune system and epithelial-immune cell interactions over a
lifetime need to be better understood. Research examining the
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immortalization barrier to breast cancer progression is in its
infancy, but may identify new targets of this rate-limiting step in
cancer progression.
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